Abstract |
This study was designed to compare the pharmacokinetic and short-term pharmacodynamic profile of extended-release glipizide GITS ( Glucotrol XL) given in a dosage of 20 mg once daily with that of immediate-release glipizide ( Glucotrol) 10mg twice daily in patients with type II diabetes mellitus. In an open-label, randomized, two-way crossover study, each glipizide formulation was administered for 5 days. Serial blood samples were drawn at baseline and on the 5th day of each treatment phase for measurement of glipizide, glucose, insulin, and C-peptide concentrations. At steady state, the mean Cmax after immediate-release glipizide was significantly greater than after glipizide GITS, and the tmax was considerably shorter. Although the mean Cmin with glipizide GITS was about 80% higher than with immediate-release glipizide, the mean AUC0-24 was significantly lower. Despite the lower plasma concentrations with glipizide GITS in this short-term study, the two formulations had similar effects on serum concentrations of glucose, insulin, and C-peptide. The absence of a pronounced peak plasma concentration with the GITS formulation might confer advantages in terms of maintaining clinical effectiveness and reducing the potential to cause adverse effects.
|
Authors | Menger Chung, Ione Kourides, William Canovatchel, Tamara Sutfin, Michael Messig, Rochelle L Chaiken |
Journal | Journal of clinical pharmacology
(J Clin Pharmacol)
Vol. 42
Issue 6
Pg. 651-7
(Jun 2002)
ISSN: 0091-2700 [Print] England |
PMID | 12043953
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Glipizide
|
Topics |
- Adult
- Aged
- Blood Glucose
(analysis)
- Cross-Over Studies
- Diabetes Mellitus, Type 2
(drug therapy)
- Glipizide
(administration & dosage, pharmacokinetics, pharmacology)
- Humans
- Hypoglycemic Agents
(administration & dosage)
- Insulin
(blood)
- Male
- Middle Aged
|